pharmaphorum January 14, 2026
Novo Nordisk’s new chief executive, Mike Doustdar, has told the JPM Healthcare conference that the key to competing in the GLP-1 agonist category for weight loss will be to make the most of cash-pay channels.
In his first major strategy update since taking over from Lars Fruergaard Jørgensen last year, Doustdar conceded the company has made mistakes in the last year or so – including casting its net too wide in the GLP-1 category – and vowed to keep a tighter focus on its core area of obesity, weight-related diseases, diabetes and, to a lesser extent, rare diseases.
Near-term, that means making the most of its newly approved Wegovy (semaglutide) pill, now rolling out across the US, and keeping ahead...
Today's Sponsors
Today's Sponsor